Costs of subcutaneous and intravenous administration of trastuzumab for patients with HER2-positive breast cancer

Jens Olsen; Kenneth Forsstrøm Jensen; Daniel Sloth Olesen; Ann Knoop

doi:10.2217/cer-2017-0048

Costs of subcutaneous and intravenous administration of trastuzumab for patients with HER2-positive breast cancer

Jens Olsen, Kenneth Forsstrøm Jensen, Daniel Sloth Olesen, Ann Knoop

16 Citationer (Scopus)

Abstract

AIM: Trastuzumab is available in an intravenous (iv.) and a subcutaneous (sc.) formulation. The objective of this study was to estimate the costs of administration of iv. and sc. trastuzumab treatment.

MATERIALS & METHODS: Via interviews, we identified all the activities associated with iv. and sc. administration. The outcome was time estimates. To estimate the administration costs, the time estimates were valued by average gross wages.

RESULTS: The iv. administration takes longer time as infusion time is longer (25 or 85 min). The iv. administration is associated with higher cost for 17 cycles; €971 (€1858 vs €887).

CONCLUSION: sc. administration is associated with lower administration costs. Switching patients from iv. to sc. would make it possible to treat more patients without increasing the personnel resources.

Originalsprog	Engelsk
Tidsskrift	Journal of Comparative Neurology
Vol/bind	7
Udgave nummer	5
Sider (fra-til)	411-419
ISSN	0021-9967
DOI	https://doi.org/10.2217/cer-2017-0048
Status	Udgivet - 2018

Adgang til dokumentet

10.2217/cer-2017-0048

Citationsformater

@article{2682e4d5e8604493ac1cbcf6ed65ec05,

title = "Costs of subcutaneous and intravenous administration of trastuzumab for patients with HER2-positive breast cancer",

abstract = "AIM: Trastuzumab is available in an intravenous (iv.) and a subcutaneous (sc.) formulation. The objective of this study was to estimate the costs of administration of iv. and sc. trastuzumab treatment.MATERIALS & METHODS: Via interviews, we identified all the activities associated with iv. and sc. administration. The outcome was time estimates. To estimate the administration costs, the time estimates were valued by average gross wages.RESULTS: The iv. administration takes longer time as infusion time is longer (25 or 85 min). The iv. administration is associated with higher cost for 17 cycles; €971 (€1858 vs €887).CONCLUSION: sc. administration is associated with lower administration costs. Switching patients from iv. to sc. would make it possible to treat more patients without increasing the personnel resources.",

keywords = "Journal Article",

author = "Jens Olsen and Jensen, {Kenneth Forsstr{\o}m} and Olesen, {Daniel Sloth} and Ann Knoop",

year = "2018",

doi = "10.2217/cer-2017-0048",

language = "English",

volume = "7",

pages = "411--419",

journal = "Journal of Comparative Neurology",

issn = "0021-9967",

publisher = "John/Wiley & Sons, Inc. John/Wiley & Sons Ltd",

number = "5",

}

TY - JOUR

T1 - Costs of subcutaneous and intravenous administration of trastuzumab for patients with HER2-positive breast cancer

AU - Olsen, Jens

AU - Jensen, Kenneth Forsstrøm

AU - Olesen, Daniel Sloth

AU - Knoop, Ann

PY - 2018

Y1 - 2018

N2 - AIM: Trastuzumab is available in an intravenous (iv.) and a subcutaneous (sc.) formulation. The objective of this study was to estimate the costs of administration of iv. and sc. trastuzumab treatment.MATERIALS & METHODS: Via interviews, we identified all the activities associated with iv. and sc. administration. The outcome was time estimates. To estimate the administration costs, the time estimates were valued by average gross wages.RESULTS: The iv. administration takes longer time as infusion time is longer (25 or 85 min). The iv. administration is associated with higher cost for 17 cycles; €971 (€1858 vs €887).CONCLUSION: sc. administration is associated with lower administration costs. Switching patients from iv. to sc. would make it possible to treat more patients without increasing the personnel resources.

AB - AIM: Trastuzumab is available in an intravenous (iv.) and a subcutaneous (sc.) formulation. The objective of this study was to estimate the costs of administration of iv. and sc. trastuzumab treatment.MATERIALS & METHODS: Via interviews, we identified all the activities associated with iv. and sc. administration. The outcome was time estimates. To estimate the administration costs, the time estimates were valued by average gross wages.RESULTS: The iv. administration takes longer time as infusion time is longer (25 or 85 min). The iv. administration is associated with higher cost for 17 cycles; €971 (€1858 vs €887).CONCLUSION: sc. administration is associated with lower administration costs. Switching patients from iv. to sc. would make it possible to treat more patients without increasing the personnel resources.

KW - Journal Article

U2 - 10.2217/cer-2017-0048

DO - 10.2217/cer-2017-0048

M3 - Journal article

C2 - 29199854

SN - 0021-9967

VL - 7

SP - 411

EP - 419

JO - Journal of Comparative Neurology

JF - Journal of Comparative Neurology

IS - 5

ER -

Costs of subcutaneous and intravenous administration of trastuzumab for patients with HER2-positive breast cancer

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater